share_log

Fu Yu Reverses Losses With $72k Net Profit in H1 2024

Fu Yu Reverses Losses With $72k Net Profit in H1 2024

富裕集團在2024上半年實現淨利潤7.2萬。
Singapore Business Review ·  08/08 10:26

Revenue grew 78% to $126.7m.

營業收入增長了78%至12670萬美元。

Fu Yu reported a net profit of $72,000 for H1 2024, rebounding from the $3.9m loss incurred a year ago.

富裕集團報告2024年上半年淨利潤爲72,000美元,從一年前的390萬美元虧損中反彈。

Revenue for the period grew 78.0% to $126.7m, boosted by stronger contributions from both the manufacturing and supply chain management segments.

該期營業收入增長78.0%,至12670萬美元,由於製造業和供應鏈管理部門的貢獻增強。

Revenue from its supply chain management arm, Fu Yu Supply Chain Solutions (FYSCS) more than tripled to $72.0m from $18.6m due to higher demand amidst a global economic recovery.

由於全球經濟復甦帶來的需求增加,富裕供應鏈解決方案(FYSCS)的營業收入猛增至7200萬美元,是1860萬美元的三倍多。

Meanwhile, gross profit from the manufacturing segment rose 12.9% to $7.0m from $6.2m a year ago.

與一年前的620萬美元相比,製造業部門的毛利潤從700萬美元上升了12.9%。

In a bourse filing, the company said that its manufacturing business grew 4% to $54.8m in H1 2024, driven by higher sales from Singapore and Malaysia, partially offset by lower turnover in China.

在交易所提交的文件中,該公司表示,其製造業務在2024年上半年增長了4%,達到5480萬美元,受新加坡和馬來西亞銷售增加驅動,部分抵消了中國業務的萎縮。

Revenue from Singapore and Malaysia rose 6.6% to $21.0m and 39.1% to $17.8m, respectively, whilst revenue from China fell 20.4% to $16.0m. In addition, the higher-margin biomedical segment contributed 3.0% to total revenue for H1 2024.

新加坡和馬來西亞的營業收入分別增長了6.6%和39.1%,分別達到2100萬美元和1780萬美元,而來自中國的營業收入下降了20.4%,只有1600萬美元。此外,高利潤的生物醫藥部門爲2024年上半年總營收做出了3.0%的貢獻。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論